For GIST patients with localized disease who underwent surgical treatment, the evaluation of c-KIT/PDGFRα molecular alterations together with other clinicopathological factors, including tumor site/size, mitotic rate, and proliferation index, is crucial to predict the potential risk of recurrence and ultimately decide if patients are candidate to receive adjuvant therapy with imatinib mesylate [1]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.